{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:05Z","timestamp":1793135105161,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute Cancer Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.critrevonc.2023.104236","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:01:43Z","timestamp":1702987303000},"page":"104236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Predictors of response to neoadjuvant therapy in urothelial cancer"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-1567","authenticated-orcid":false,"given":"Nishita","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gliceida Galarza","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Mathew Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Cancer Meta-analysis, C","year":"2005","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-018-0536-6","article-title":"Increased CD4(+) T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients","volume":"10","author":"Ahlen Bergman","year":"2018","journal-title":"Clin. Epigenetics"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib4","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","article-title":"Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery","volume":"16","author":"Almassi","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104236_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharm. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urolonc.2018.11.011","article-title":"A delay >\/=8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging","volume":"37","author":"Audenet","year":"2019","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study(\u2606)","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clgc.2016.05.004","article-title":"Low pretreatment neutrophil-to-lymphocyte ratio predicts for good outcomes in patients receiving neoadjuvant chemotherapy before radical cystectomy for muscle invasive bladder cancer","volume":"15","author":"Buisan","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib12","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1016\/j.clgc.2017.01.024","article-title":"Role of inflammation in the perioperative management of urothelial bladder cancer with squamous-cell features: impact of neutrophil-to-lymphocyte ratio on outcomes and response to neoadjuvant chemotherapy","volume":"15","author":"Buisan","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib13","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4515","article-title":"Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06\/17","volume":"40","author":"Cathomas","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib15","article-title":"Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial","volume":"40","author":"Chanza","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cncr.29843","article-title":"Treatment of muscle-invasive bladder cancer: a systematic review","volume":"122","author":"Chou","year":"2016","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104236_bib18","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104236_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1464-410x.2000.00612.x","article-title":"Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy","volume":"85","author":"Cooke","year":"2000","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104236_bib21","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1570","article-title":"LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer","author":"Dudek","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib25","first-page":"24","article-title":"Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma","volume":"13","author":"Duplisea","year":"2019","journal-title":"Can. Urol. Assoc. J."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrurol.2017.179","article-title":"Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy","volume":"15","author":"Felsenstein","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.juro.2017.08.086","article-title":"Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the national cancer database","volume":"199","author":"Fischer-Valuck","year":"2018","journal-title":"J. Urol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4506","article-title":"SWOG S1314: a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer","volume":"37","author":"Flaig","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.536","article-title":"SWOG S1314: a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up","volume":"40","author":"Flaig","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdq333","article-title":"BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer","volume":"22","author":"Font","year":"2011","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib32","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104236_bib33","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4503","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257","volume":"39","author":"Galsky","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib36","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2023.104236_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.397","article-title":"A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis","volume":"39","author":"Geynisman","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104236_bib39","doi-asserted-by":"crossref","first-page":"469 e1","DOI":"10.1016\/j.urolonc.2018.07.012","article-title":"Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: a national cancer database analysis","volume":"36","author":"Gild","year":"2018","journal-title":"Urol. Oncol."},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.535","article-title":"Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma","volume":"40","author":"Goubet","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-18-2512","article-title":"DNA damage response gene alterations in urothelial cancer: ready for practice?","volume":"25","author":"Grivas","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urolonc.2019.11.004","article-title":"Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy","volume":"38","author":"Grivas","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib44","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.eururo.2015.02.043","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","author":"Groenendijk","year":"2015","journal-title":"Eur Urol. In press"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104236_bib45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155503","article-title":"Platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"11","author":"Guancial","year":"2016","journal-title":"PLoS One"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib48","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.juro.2015.06.085","article-title":"Emmprin expression predicts response and survival following cisplatin containing chemotherapy for bladder cancer: a validation study","volume":"194","author":"Hemdan","year":"2015","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/21681805.2018.1439527","article-title":"Choline-phosphate cytidylyltransferase-alpha as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder","volume":"52","author":"Hemdan","year":"2018","journal-title":"Scand. J. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib50","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/j.clgc.2018.02.007","article-title":"Optimization of patient selection for neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"16","author":"Hensley","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104236_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.015","article-title":"Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study","volume":"69","author":"Hermans","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"Supplement 5","key":"10.1016\/j.critrevonc.2023.104236_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000002536.07","article-title":"PD10-07update of truce-01: neoadjuvant tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma","volume":"207","author":"Hu","year":"2022","journal-title":"J. Urol."},{"issue":"16","key":"10.1016\/j.critrevonc.2023.104236_bib53","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of, T","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104236_bib54","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104236_bib55","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/BLC-170133","article-title":"The prognostic role of the change in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: a retrospective, multi-institutional study","volume":"4","author":"Kaiser","year":"2018","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1349-7006.1998.tb00551.x","article-title":"Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas","volume":"89","author":"Kakehi","year":"1998","journal-title":"Jpn J. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3892\/ol.2012.689","article-title":"Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer","volume":"4","author":"Kawashima","year":"2012","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib61","first-page":"495","article-title":"Copper transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients","volume":"36","author":"Kilari","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2023.104236_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2019.01.019","article-title":"Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"135","author":"Kim","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00345-013-1128-x","article-title":"The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer","volume":"32","author":"Kim","year":"2014","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.12.005","article-title":"Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder","volume":"33","author":"Kiss","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib65","unstructured":"Krimphove, M.J., et al., Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus, 2019."},{"issue":"32","key":"10.1016\/j.critrevonc.2023.104236_bib66","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1073\/pnas.0610292104","article-title":"A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery","volume":"104","author":"Lee","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib67","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.clon.2016.07.007","article-title":"Association between the absolute baseline lymphocyte count and response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer","volume":"28","author":"Leibowitz-Amit","year":"2016","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104236_bib69","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104236_bib71","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdl289","article-title":"Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment","volume":"17","author":"Maluf","year":"2006","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104236_bib72","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2023.104236_bib73","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2021.08.055","article-title":"659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)","volume":"32","author":"Martinez Chanza","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32169","article-title":"Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer","author":"Martini","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib75","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.juro.2012.06.018","article-title":"Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?","volume":"188","author":"Mertens","year":"2012","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib76","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1016\/j.clgc.2017.07.008","article-title":"Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder","volume":"15","author":"Minato","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib77","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.clgc.2016.07.014","article-title":"Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy","volume":"15","author":"Moschini","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib78","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clgc.2013.10.002","article-title":"Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder","volume":"12","author":"Mossanen","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib79","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10147-016-1029-2","article-title":"The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy","volume":"22","author":"Murasawa","year":"2017","journal-title":"Int J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib81","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16510","article-title":"Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423)","volume":"39","author":"Natesan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib82","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (Version 3.2019). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf Accessed June 20, 2019."},{"issue":"34","key":"10.1016\/j.critrevonc.2023.104236_bib83","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib85","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104236_bib86","doi-asserted-by":"crossref","first-page":"734 e11","DOI":"10.1016\/j.urolonc.2021.06.011","article-title":"Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition","volume":"39","author":"Necchi","year":"2021","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib87","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3233\/BLC-170110","article-title":"Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to neoadjuvant chemotherapy?","volume":"3","author":"Nguyen","year":"2017","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib88","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/cncr.30422","article-title":"Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710","volume":"123","author":"Ojerholm","year":"2017","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104236_bib89","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.30871","article-title":"Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710","volume":"123","author":"Ojerholm","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104236_bib90","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.urolonc.2018.02.018","article-title":"Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy","volume":"36","author":"Ornstein","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib91","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0561","article-title":"Efficacy of split schedule vs. conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer","author":"Osterman","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104236_bib92","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.urolonc.2012.06.014","article-title":"Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy","volume":"31","author":"Ozcan","year":"2013","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib93","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.juro.2014.11.003","article-title":"The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival","volume":"193","author":"Parker","year":"2015","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib94","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104236_bib95","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104236_bib96","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \"primary\" and \"secondary\" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur. Urol."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104236_bib98","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib99","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib100","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clgc.2015.09.013","article-title":"Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"14","author":"Pokuri","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib101","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2353\/ajpath.2009.090155","article-title":"Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy","volume":"175","author":"Pollard","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104236_bib102","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib103","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder","volume":"171","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104236_bib105","doi-asserted-by":"crossref","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: an intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib106","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.542","article-title":"Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial","volume":"38","author":"Rodriguez-Moreno","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2023.104236_bib107","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib108","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1200\/JCO.1995.13.6.1384","article-title":"Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC","volume":"13","author":"Sarkis","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104236_bib109","first-page":"6453","article-title":"Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: a prospective clinical trial based on cisplatin feasibility","volume":"37","author":"Schinzari","year":"2017","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104236_bib110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-410X.2010.09900.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib111","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.clgc.2015.02.001","article-title":"Neutrophil-lymphocyte ratio and pathological response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"13","author":"Seah","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib112","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"issue":"Supplement 5","key":"10.1016\/j.critrevonc.2023.104236_bib113","article-title":"MP23-18preliminary results of a urine-based dna methylation test to monitor response to neoadjuvant therapy in muscle-invasive bladder cancer","volume":"207","author":"Seyedian","year":"2022","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib114","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/003655902762467567","article-title":"Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2","volume":"36","author":"Sherif","year":"2002","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib115","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib116","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib117","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000489013","article-title":"Sarcopenia as a predictive factor for response to upfront cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder cancer","volume":"101","author":"Stangl","year":"2018","journal-title":"Urol. Int"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib118","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.plipres.2008.01.002","article-title":"Transcriptional regulation of phosphatidylcholine biosynthesis","volume":"47","author":"Sugimoto","year":"2008","journal-title":"Prog. Lipid Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104236_bib119","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3233\/BLC-160066","article-title":"Micropapillary bladder cancer: insights from the national cancer database","volume":"2","author":"Sui","year":"2016","journal-title":"Bladder Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104236_bib120","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00345-016-1962-8","article-title":"Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer","volume":"35","author":"Sui","year":"2017","journal-title":"World J. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104236_bib121","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104236_bib122","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-04-1988","article-title":"Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling","volume":"11","author":"Takata","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib123","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1038\/s41598-017-12892-5","article-title":"Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer","volume":"7","author":"Tervahartiala","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib124","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.juro.2010.04.081","article-title":"Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients","volume":"184","author":"Tilki","year":"2010","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21681805.2019.1575467","article-title":"Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?","volume":"53","author":"Turker","year":"2019","journal-title":"Scand. J. Urol."},{"key":"10.1016\/j.critrevonc.2023.104236_bib126","unstructured":"United States National Library of Medicine. Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03609216. Retrieved September 2, 2019."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib127","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jjco\/hyl121","article-title":"HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer","volume":"37","author":"Urushibara","year":"2007","journal-title":"Jpn J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104236_bib128","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104236_bib129","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00345-018-2361-0","article-title":"Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy","volume":"37","author":"Vasdev","year":"2019","journal-title":"World J. Urol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104236_bib131","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.104236_bib132","unstructured":"Werntz, R.P., et al., The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. Eur Urol Focus, 2018."},{"key":"10.1016\/j.critrevonc.2023.104236_bib133","doi-asserted-by":"crossref","first-page":"32804","DOI":"10.1038\/srep32804","article-title":"CD147\/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104236_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/biom6030037","article-title":"An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer","volume":"6","author":"Xylinas","year":"2016","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2023.104236_bib135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ebiom.2018.06.011","article-title":"Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy","volume":"35","author":"Yang","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib136","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/BLC-160080","article-title":"Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer","volume":"3","author":"Zargar","year":"2017","journal-title":"Bladder Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104236_bib137","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy","volume":"199","author":"Zargar","year":"2018","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104236_bib138","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clgc.2015.08.006","article-title":"Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation","volume":"14","author":"Zargar-Shoshtari","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6_suppl","key":"10.1016\/j.critrevonc.2023.104236_bib139","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.552","article-title":"Longitudinal personalized urinary tumor DNA analysis in muscle-invasive bladder cancer from the neoadjuvant immunotherapy trial RJBLC-I2N003","volume":"40","author":"Zhang","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:52:55Z","timestamp":1760903575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823003244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":139,"alternative-id":["S1040842823003244"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104236","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of response to neoadjuvant therapy in urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104236"}}